-
ViewMind Applauded by Frost & Sullivan for Its One-of-a-Kind Digital Biomarker Technology for Neurocognitive Disorders
prnasia
May 26, 2021
Based on its recent analysis of the global market for digital biomarkers for neurocognitive disorders, Frost & Sullivan recognizes ViewMind with the 2021 Global Enabling Technology Leadership Award. ViewMind's reliable, non-invasive, affordable, and ...
-
Luye Pharma's Innovative Alzheimer's Disease Therapy Rivastigmine Multi-Day Transdermal Patch Now Eligible for Marketing Authorization in Several EU Countries
prnasia
May 24, 2021
Luye Pharma Group today announced the successful completion of the Decentralised Registration Procedures (DCPs) for its Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD).
-
GemVax's highly promising Phase II Alzheimer's disease clinical trial results targeting telomerase published in prestigious Alzheimer's Research & Therapy' journal
prnasia
March 30, 2021
GemVax & KAEL Co., Ltd. has announced that a paper on GV1001, a novel Alzheimer's treatment based on telomerase modification, was published on March 26th in the SCI-grade international journal 'Alzheimer's Research & Therapy'.
-
Asceneuron Receives Award from Alzheimer's Drug Discovery Foundation
americanpharmaceuticalreview
March 15, 2021
Asceneuron announced the receipt of a $2.2 million award from the Alzheimer's Drug Discovery Foundation (ADDF) for a first in human Phase I study of the Company's next generation O-GlcNAcase inhibitor, ASN51.
-
Biohaven Provides Update on Phase 2/3 Trial, Alzheimer's Program
americanpharmaceuticalreview
January 20, 2021
Biohaven Pharmaceutical has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as a symptomatic treatment in mild-to-moderate Alzheimer's disease (AD).
-
High LDL Cholesterol Tied to Early-Onset Alzheimer's
drugs
May 30, 2019
High LDL Cholesterol Tied to Early-Onset Alzheimer's.
-
More evidence that blood tests can detect the risk of Alzheimer's
Sciencedaily
April 24, 2019
A new study confirms that a simple blood test can reveal whether there is accelerating nerve cell damage in the brain.
-
Of Mice and Men: New Light and Sound Combination Therapy May Treat Alzheimer's
biospace
April 22, 2019
While Alzheimer's patients can be treated for symptoms or pain, the disease has no cure, and no current treatment can slow its progression.
-
Alzheimer’s trial discontinued due to inefficiency
pharmatimes
March 27, 2019
Biogen and Eisai have stopped two global Phase III trials of the Alzheimer's drug aducanumab, after interim analyses indicated that the agent was ineffective and would not meet the primary endpoint.
-
Study connects Alzheimer's with hearing disorder
biospectrumasia
January 22, 2019
This study builds on earlier research that analyzed how addressing memory problems could benefit older adults seeking hearing loss treatment.